Review: Imatinib plasma trough levels in the management of CML: Ready for prime time?
Mauro
Michael J
MJ
Knight Cancer Institute, Center for Hematologic Malignancies, Oregon Health & Science University, Portland, 97239, USA. maurom@ohsu.edu
D001549:Benzamides; D016903:Drug Monitoring; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D010879:Piperazines / Q000097:blood* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000097:blood* / Q000627:therapeutic use; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate